Participants 62 116 5
patients with implantable cardioverter defibrillators.
Participants 199 320 6
anti-tachycardia pacing (ATP) and shock-terminated events in patients with implantable cardioverter defibrillators (ICDs)
Participants 699 862 9
A total of 172 patients were randomized to daily treatment with placebo, 35 mg, 75 mg, or 125 mg of oral AZ in this dose-ranging pilot study of patients with ICDs.
Participants 863 1017 5
The majority of patients had a history of documented remote myocardial infarction and congestive heart failure New York Heart Association class II or III.
